NCT02658890: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread.

NCT02658890
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active central nervous system (CNS) metastases& CNS metastases as the only sites of disease
https://ClinicalTrials.gov/show/NCT02658890

Comments are closed.

Up ↑